Mengyuan Fu
Postdoctoral FellowAbout
Research
Publications
2026
Secondary use and scholarly impact of a portfolio of clinical trials with shared individual participant level data: cross sectional study.
Taherifard E, Mooghali M, Hakimian H, Mane S, Fu M, Bamford S, Berlin J, Childers K, Desai N, Gross C, Hewens D, Lehman R, Ritchie J, Sargood T, Waldstreicher J, Wallach J, Willeford M, Krumholz H, Ross J. Secondary use and scholarly impact of a portfolio of clinical trials with shared individual participant level data: cross sectional study. The BMJ 2026, 394: e100460. PMID: 42686366, DOI: 10.1136/bmj-2026-100460.Peer-Reviewed Original ResearchAssociation of β-lactam allergy labels with antibiotic use patterns, clinical outcomes and economic burden in China: a retrospective observational study
Wushouer H, Xiao R, Hu L, Du F, Li W, Fu M, Shi L, Guan X. Association of β-lactam allergy labels with antibiotic use patterns, clinical outcomes and economic burden in China: a retrospective observational study. BMC Infectious Diseases 2026 DOI: 10.1186/s12879-026-14192-8.Peer-Reviewed Original ResearchEfficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025
Li C, Fu M, Berg K, Wallach J, Ling K, Wei R, Shi L, Ross J, Guan X. Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025. Neurology 2026, 107: e218373. PMID: 42492033, PMCID: PMC13445500, DOI: 10.1212/wnl.0000000000218373.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDrug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics
Fu M, Wallach J, So A, Doernberg H, Li X, Guan X, Ramachandran R, Ross J. Drug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics. Health Affairs Scholar 2026, 4: qxag181. PMID: 42482967, PMCID: PMC13387065, DOI: 10.1093/haschl/qxag181.Peer-Reviewed Original ResearchNovel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks
Fu M, Ghosh R, Taherifard E, Ramachandran R, Ross J. Novel Drug Launches in Most-Favored-Nation Countries and Medicare Pricing Benchmarks. JAMA Health Forum 2026, 7: e262340. PMID: 42536387, PMCID: PMC13428281, DOI: 10.1001/jamahealthforum.2026.2340.Peer-Reviewed Original ResearchEligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021
Ma Z, Zhang Y, Chen D, Fu M, Han K, Zhang Y, Ross J, Shi L, An Z, Guan X. Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021. Cancer 2026, 132: e70425. PMID: 42046201, DOI: 10.1002/cncr.70425.Peer-Reviewed Original ResearchPsychotropic medication prescribing for patients with insomnia comorbid with depressive or anxiety disorders in primary healthcare facilities in Beijing
Fu M, Li C, Zhou X, Gong Z, Zhu Y, Ding Y, Ling K, Wang F, Shi L, Guan X. Psychotropic medication prescribing for patients with insomnia comorbid with depressive or anxiety disorders in primary healthcare facilities in Beijing. BJPsych Open 2026, 12: e55. PMID: 41640068, PMCID: PMC12926887, DOI: 10.1192/bjo.2025.10967.Peer-Reviewed Original Research
2025
Peer effects on appropriate antibiotic prescribing within a patient-sharing physician network in China
Gong Z, Fu M, Hu H, Li C, Ling K, Li H, Lin H, Shen P, Zhu D, Shi L, Guan X. Peer effects on appropriate antibiotic prescribing within a patient-sharing physician network in China. Communications Medicine 2025, 5: 529. PMID: 41258442, PMCID: PMC12727714, DOI: 10.1038/s43856-025-01248-0.Peer-Reviewed Original ResearchStrength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner A, Ross J, Guan X. Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology 2025, 26: 1252-1260. PMID: 40782821, DOI: 10.1016/s1470-2045(25)00329-8.Peer-Reviewed Original ResearchAnticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022
Fu M, Ling K, Gong Z, Dong S, Li H, Wang F, Xu Y, Shi L, Ross J, Guan X. Anticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022. Thrombosis Research 2025, 253: 109417. PMID: 40752480, DOI: 10.1016/j.thromres.2025.109417.Commentaries, Editorials and Letters
News
Get In Touch
Contacts
Email